Interventions for latent autoimmune diabetes (LADA) in adults

Brophy, Sinéad; Brunt, Huw; Davies, Helen; Mannan, Sopna; Williams, Rhys

doi:10.1002/14651858.cd006165.pub2

Cited by 41 publications

(52 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because patients with LADA also exhibit insulin resistance like that in type 2 diabetic patients, they may require a different therapeutic approach than the usual type 2 diabetic patients. Sulfonylureas are generally not recommended as the first-line therapy for LADA because these drugs may bring about earlier insulin dependence [36]. As was shown in the present study, the clinical characteristics of LADA in Korea may be different from those in Western countries; it may be necessary to develop a therapeutic strategy unique to Korean patients.…”

Section: Discussionmentioning

confidence: 74%

Prevalence and Clinical Characteristics of Recently Diagnosed Type 2 Diabetes Patients with Positive Anti-Glutamic Acid Decarboxylase Antibody

Hwangbo

Kim

et al. 2012

Diabetes Metab J

View full text Add to dashboard Cite

BackgroundLatent autoimmune diabetes in adults (LADA) refers to a specific type of diabetes characterized by adult onset, presence of islet auto-antibodies, insulin independence at the time of diagnosis, and rapid decline in β-cell function. The prevalence of LADA among patients with type 2 diabetes varies from 2% to 20% according to the study population. Since most studies on the prevalence of LADA performed in Korea were conducted in patients who had been tested for anti-glutamic acid decarboxylase antibody (GADAb), a selection bias could not be excluded. In this study, we examined the prevalence and clinical characteristics of LADA among adult patients recently diagnosed with type 2 diabetes.MethodsWe included 462 patients who were diagnosed with type 2 diabetes within 5 years from the time this study was performed. We measured GADAb, fasting insulin level, fasting C-peptide level, fasting plasma glucose level, HbA1c, and serum lipid profiles and collected data on clinical characteristics.ResultsThe prevalence of LADA was 4.3% (20/462) among adult patients with newly diagnosed type 2 diabetes. Compared with the GADAb-negative patients, the GADAb-positive patients had lower fasting C-peptide levels (1.2±0.8 ng/mL vs. 2.0±1.2 ng/mL, P=0.004). Other metabolic features were not significantly different between the two groups.ConclusionThe prevalence of LADA is 4.3% among Korean adult patients with recently diagnosed type 2 diabetes. The Korean LADA patients exhibited decreased insulin secretory capacity as reflected by lower C-peptide levels.

show abstract

Section: Discussionmentioning

confidence: 74%

Prevalence and Clinical Characteristics of Recently Diagnosed Type 2 Diabetes Patients with Positive Anti-Glutamic Acid Decarboxylase Antibody

Hwangbo

Kim

et al. 2012

Diabetes Metab J

View full text Add to dashboard Cite

show abstract

“…Although there is a good proportion of patients with LADA, surprisingly, there are only a few studies that have evaluated interventions for this group, and several others are ongoing (15). …”

Section: Therapeutic Interventionsmentioning

confidence: 99%

β-Cell Protection and Therapy for Latent Autoimmune Diabetes in Adults

2009

View full text Add to dashboard Cite

“…Conversely, therapy options such as sulfonylureas that increase the rate of deterioration of C-peptide secretion, further depleting insulin levels, should be avoided (14–20). …”

Section: Resultsmentioning

confidence: 99%